A 92-year-old woman with normal systolic function had recently begun using the newly approved phosphodiesterase III inhibitor cilostazol when she was admitted with lower-extremity pain. Cilostazol is
BackgroundDrug-induced gingival overgrowth (DIGO) as an interdisciplinary clinical challenge, faces dual therapeutic barriers due to its unclear pathogenesis and high recurrence rate, forcing clinicia
Data on hyperkalemia frequency among chronic kidney disease (CKD) patients receiving renin-angiotensin aldosterone system inhibitors (RAASis) and its impact on subsequent RAASi treatment are limited.
